Literature DB >> 11853556

The mechanism of aggrecan release from cartilage differs with tissue origin and the agent used to stimulate catabolism.

Robert Sztrolovics1, Robert J White, Peter J Roughley, John S Mort.   

Abstract

The mechanisms of aggrecan degradation in adult human articular, adult bovine nasal and fetal bovine epiphyseal cartilage in response to either interleukin-1beta (IL-1beta) or retinoic acid were compared using an explant culture system. Bovine nasal cartilage cultured with either IL-1beta or retinoic acid exhibited significant release of glycosaminoglycan (GAG). For both factors, aggrecan proteolysis occurred predominantly at the 'aggrecanase' site, with no evidence for the action of matrix metalloproteinases, and resulted in the appearance of the corresponding G1 fragment in tissue extracts and in culture media. In human cartilage, little effect of IL-1beta was seen, but abundant release of GAG occurred in the presence of retinoic acid, with evidence of aggrecanase action. Treatment of fetal epiphyseal cartilage with retinoic acid resulted in significant GAG release, whereas treatment with IL-1beta did not. In the retinoic acid-treated tissue, however, no evidence for the cleavage of aggrecan in the interglobular region was apparent. Thus, in the fetal system, agents in addition to aggrecanase and matrix metalloproteinases appear to be active. Taken together, these data demonstrate that the pathways utilized for aggrecan catabolism may vary between different cartilages for a given stimulatory agent, and that, for a given tissue, different factors may elicit aggrecan release via different pathways.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11853556      PMCID: PMC1222408          DOI: 10.1042/0264-6021:3620465

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  41 in total

1.  Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints.

Authors:  M W Lark; E K Bayne; J Flanagan; C F Harper; L A Hoerrner; N I Hutchinson; I I Singer; S A Donatelli; J R Weidner; H R Williams; R A Mumford; L S Lohmander
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

2.  Inhibition of cartilage degradation and changes in physical properties induced by IL-1beta and retinoic acid using matrix metalloproteinase inhibitors.

Authors:  L J Bonassar; J D Sandy; M W Lark; A H Plaas; E H Frank; A J Grodzinsky
Journal:  Arch Biochem Biophys       Date:  1997-08-15       Impact factor: 4.013

3.  The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis.

Authors:  L S Lohmander; P J Neame; J D Sandy
Journal:  Arthritis Rheum       Date:  1993-09

4.  Stromelysin, tissue inhibitor of metalloproteinases and proteoglycan fragments in human knee joint fluid after injury.

Authors:  L S Lohmander; L A Hoerrner; L Dahlberg; H Roos; S Björnsson; M W Lark
Journal:  J Rheumatol       Date:  1993-08       Impact factor: 4.666

5.  Activation of procathepsin B in human hepatoma cells: the conversion into the mature enzyme relies on the action of cathepsin B itself.

Authors:  L Mach; H Schwihla; K Stüwe; A D Rowan; J S Mort; J Glössl
Journal:  Biochem J       Date:  1993-07-15       Impact factor: 3.857

6.  Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis.

Authors:  L S Lohmander; L A Hoerrner; M W Lark
Journal:  Arthritis Rheum       Date:  1993-02

7.  Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture.

Authors:  T E Cawston; A J Ellis; G Humm; E Lean; D Ward; V Curry
Journal:  Biochem Biophys Res Commun       Date:  1995-10-04       Impact factor: 3.575

8.  Human cartilage is degraded by rheumatoid arthritis synovial fluid but not by recombinant cytokines in vitro.

Authors:  A P Hollander; R M Atkins; D M Eastwood; P A Dieppe; C J Elson
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

9.  Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro.

Authors:  C E Hughes; B Caterson; A J Fosang; P J Roughley; J S Mort
Journal:  Biochem J       Date:  1995-02-01       Impact factor: 3.857

10.  VDIPEN, a metalloproteinase-generated neoepitope, is induced and immunolocalized in articular cartilage during inflammatory arthritis.

Authors:  I I Singer; D W Kawka; E K Bayne; S A Donatelli; J R Weidner; H R Williams; J M Ayala; R A Mumford; M W Lark; T T Glant
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

View more
  22 in total

1.  Variations in aggrecan structure modulate its susceptibility to aggrecanases.

Authors:  Peter J Roughley; James Barnett; Fengrong Zuo; John S Mort
Journal:  Biochem J       Date:  2003-10-01       Impact factor: 3.857

2.  Mature bovine articular cartilage contains abundant aggrecan that is C-terminally truncated at Ala719-Ala720, a site which is readily cleaved by m-calpain.

Authors:  Hidefumi Oshita; John D Sandy; Kiichi Suzuki; Atsushi Akaike; Yun Bai; Tomohiro Sasaki; Katsuji Shimizu
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

3.  Detrimental effects of discectomy on intervertebral disc biology can be decelerated by growth factor treatment during surgery: a large animal organ culture model.

Authors:  Svenja Illien-Jünger; Young Lu; Devina Purmessur; Jillian E Mayer; Benjamin A Walter; Peter J Roughley; Sheeraz A Qureshi; Andrew C Hecht; James C Iatridis
Journal:  Spine J       Date:  2014-04-24       Impact factor: 4.166

4.  Involvement of ADAMTS5 and hyaluronidase in aggrecan degradation and release from OSM-stimulated cartilage.

Authors:  M Durigova; L Troeberg; H Nagase; P J Roughley; J S Mort
Journal:  Eur Cell Mater       Date:  2011-01-12       Impact factor: 3.942

5.  MMPs are less efficient than ADAMTS5 in cleaving aggrecan core protein.

Authors:  Michaela Durigova; Hideaki Nagase; John S Mort; Peter J Roughley
Journal:  Matrix Biol       Date:  2010-11-03       Impact factor: 11.583

6.  Matrix metalloproteinases are not essential for aggrecan turnover during normal skeletal growth and development.

Authors:  Christopher B Little; Clare T Meeker; Rosalind M Hembry; Natalie A Sims; Kate E Lawlor; Sue B Golub; Karena Last; Amanda J Fosang
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

7.  Oncostatin M in combination with tumour necrosis factor {alpha} induces a chondrocyte membrane associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or -2.

Authors:  W Hui; H E Barksby; D A Young; T E Cawston; N McKie; A D Rowan
Journal:  Ann Rheum Dis       Date:  2005-05-05       Impact factor: 19.103

8.  Link N and mesenchymal stem cells can induce regeneration of the early degenerate intervertebral disc.

Authors:  Fackson Mwale; Hong Tian Wang; Peter Roughley; John Antoniou; Lisbet Haglund
Journal:  Tissue Eng Part A       Date:  2014-06-25       Impact factor: 3.845

9.  Aggrecan, versican and type VI collagen are components of annular translamellar crossbridges in the intervertebral disc.

Authors:  James Melrose; Susan M Smith; Richard C Appleyard; Christopher B Little
Journal:  Eur Spine J       Date:  2007-10-31       Impact factor: 3.134

10.  Primary bovine intervertebral disc cells transduced with adenovirus overexpressing 12 BMPs and Sox9 maintain appropriate phenotype.

Authors:  Yejia Zhang; Dessislava Markova; Hee-Jeong Im; Wenyang Hu; Eugene J-M A Thonar; Tong-Chuan He; Howard S An; Frank M Phillips; D Greg Anderson
Journal:  Am J Phys Med Rehabil       Date:  2009-06       Impact factor: 2.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.